Results 121 to 130 of about 31,578 (263)

Efficacy of venetoclax-obinutuzumab treatment in achieving remission of acquired von Willebrand syndrome in chronic lymphocytic leukemia. [PDF]

Ann Hematol
Morelli F, Linari S, Rapolla CM, Attanasio M, Salvianti F, Sanna A.   +5 more
europepmc   +1 more source

How I Investigate Borderline Prolonged aPTT: An Integrated Laboratory Approach to Mixing Studies and Factor Analysis

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Borderline prolongation of routine clotting assays—particularly the activated partial thromboplastin time (aPTT)—is a common interpretative challenge in laboratory hematology. These reproducible but mildly prolonged results often lie just beyond the upper reference limit and can trigger unnecessary follow‐up, delays, or misinterpretation ...
Nikolaos Androulakis, Eleni Nioti, Antonios Dilintas, Christina Kalpadakis   +3 more
wiley   +1 more source

Optimizing treatment for Waldenström macroglobulinemia-associated acquired von Willebrand syndrome: a case report and literature review. [PDF]

Front Oncol
Shen K, Yang C, Ma H.
europepmc   +1 more source

Advanced Molecular Analysis in Hemophilia A in a Single Step: Next Generation Sequencing (NGS) and Copy Number Variation (CNV) Analysis

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Background Hemophilia A, an X‐linked bleeding disorder caused by pathogenic variants in the F8 gene, requires precise genetic diagnosis for optimal management. Conventional stepwise sequence and copy number variation (CNV) analyses are time‐consuming and may leave some cases unresolved.
Enise Avci Durmusalioglu, Esra Isik, Basak Durmus Ozen, Mehmet Mert Topaloglu, Nihal Karadas, Kaan Kavakli, Melike Sezgin Evim, Tolga Aslan, Erşen Kavak, Adalet Meral Gunes, Funda Tayfun Kupesiz, Alphan Kupesiz, Fahri Sahin, Tahir Atik   +13 more
wiley   +1 more source

Sushi, von Willebrand Factor Type A, EGF and Pentraxin Domain-Containing Protein 1: A Novel Fibroblast-Derived Circulating Biomarker Reflecting Cardiac Fibrosis. [PDF]

J Am Heart Assoc
Kuwahara N, Nagao M, Izawa Y, Kaneshiro K, Hashimura H, Yoshida T, Emoto T, Toba T, Tanaka H, Ishida T, Shinohara M, Otake H.   +11 more
europepmc   +1 more source

Thrombocytopenia in Pregnancy: A 5‐Year Analysis of Characteristics and Practices From a Tertiary Academic Center

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Background Moderate‐to‐severe thrombocytopenia (platelet count < 100 × 109/L) occurs in fewer than 1% of pregnancies, posing management challenges, particularly surrounding eligibility for neuraxial anesthesia. Although recent anesthesia guidelines recommend a platelet threshold ≥ 70 × 109/L, outcomes data applying these recommendations in ...
Mackenzie E. Lemieux, Ming Y. Lim
wiley   +1 more source

How I Investigate Bleeding Disorders of Unknown Cause: Current Diagnostic Pathways and Gaps in Laboratory Investigation

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Bleeding disorder of unknown cause (BDUC) constitutes the largest group of patients presenting with a mild‐to‐moderate bleeding tendency in tertiary care settings. Their clinical bleeding phenotype is characterized by mucocutaneous bleeding, as well as bleeding following surgical challenges or childbirth, and is associated with impaired health‐
Dino Mehic, Faris Karaselimovic, Tim Dreier, Johanna Gebhart   +3 more
wiley   +1 more source

Real-word evidence on healthcare resource use and associated costs in on-demand users of replacement therapies in von Willebrand disease in France: the FORvWARD study. [PDF]

J Comp Eff Res
Polack B, Nerich V, Micallef CM, Trossaërt M, Biron-Andreani C, Bornier N, Chatelanaz C, Favre-Besse F, Beoletto J, Née M, Belhassen M, Lefèvre C, Pouvourville G.   +12 more
europepmc   +1 more source

Testing for Non‐Severe Heritable Platelet Function Disorders

International Journal of Laboratory Hematology, EarlyView.
ABSTRACT Heritable platelet function disorders (HPFD) are a diverse group of bleeding disorders characterised by a primary qualitative defect in platelet function rather than platelet number. HPFD may be broadly categorised according to the severity of bleeding, with Glanzmann thrombasthenia and Bernard Soulier syndrome classically considered severe ...
Kate Burley, Naomi Cornish, Maria Molina Carretero, Sarah K. Westbury   +3 more
wiley   +1 more source

Recombinant von Willebrand factor for von Willebrand disease: mechanism of action and clinical application. [PDF]

Ther Adv Hematol
Hua Z, Miao W, Zhang P, Yang R.
europepmc   +1 more source